Achieve Life Sciences to report Q1 2026 results and update on nicotine dependence drug cytisinicline on May 12.

Achieve Life Sciences will announce its first quarter 2026 financial results and provide a corporate update on May 12, 2026. The company is focused on developing cytisinicline, a plant-based drug aimed at treating nicotine dependence for smoking and vaping cessation. Cytisinicline's New Drug Application was accepted by the FDA in September 2025, with a review deadline set for June 20, 2026. This drug addresses a significant public health need, as millions of adults in the U.S. smoke or vape, and there are currently no FDA-approved treatments specifically for e-cigarette cessation.